ORIC Pharmaceuticals, Inc. (ORIC)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-03) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-04) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-23) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-05) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-18) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-12) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-06) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-11) · 99.1 | 8-K (2024-01-09) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-06) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Balance Sheets | ||
| Balance Sheets (P) | ||
| Statements of Operations and Comprehensive Loss | ||
| Statements of Stockholders' Equity | ||
| Statements of Cash Flows | ||
| Notes | ||
| Accrued Liabilities | ||
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Description of The Business | ||
| Employee Benefit Plan | — |
|
| Fair Value Measurements | ||
| Income Tax | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Investments | ||
| Investments, Available-for-sale | — |
|
| Leases | — |
|
| License Agreements and Clinical Development Collaboration | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment, Net | ||
| Stockholders' Equity and Stock-based Compensation | ||
| Subsequent Event | — |
|